Ivarmacitinib sulfate is under clinical development by Reistone Biopharma and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase III drugs for Atopic Dermatitis (Atopic Eczema) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ivarmacitinib sulfate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ivarmacitinib sulfate overview
SHR-0302 (ARQ-250) is under development for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, axial spondyloarthritis, ulcerative colitis, psoriatic arthritis, moderate to severe atopic dermatitis, vitiligo,hand eczema, alopecia areata and other inflammatory dermatoses. The drug candidate is administered orally and topically and formulated as tablet and cream. It acts by targeting JAK1 (Janus Kinase 1).
Reistone Biopharma overview
Reistone Biopharma is a clinical stage biopharmaceutical company that focused on developing novel medicines for life threatening autoimmune diseases. The company is headquartered in China.
For a complete picture of Ivarmacitinib sulfate’s drug-specific PTSR and LoA scores, buy the report here.